白蛋白结合型紫杉醇联合铂类治疗NSCLC临床疗效观察

目的评价白蛋白结合型紫杉醇联合铂类方案一线和二线治疗晚期肺癌(NSCLC)的临床疗效及毒副反应。方法 82例使用白蛋白结合型紫杉醇联合铂类治疗的NSCLC患者,分为A、B两组,计算患者的近期客观反应率(OR)、疾病控制率(RR)、疾病进展时间(TTP)、生存期(OS)、1年生存率;观察患者的毒副反应及耐受性。结果 82例患者总有效率21.95%,疾病控制率73.17%,疾病进展时间(TTP):6.3月。中位生存期:10.3月,1年生存率:36.59%。不良反应可以耐受。结论白蛋白结合型紫杉醇联合顺铂或卡铂方案是治疗晚期肺癌安全有效的化疗方案之一,可以推荐在临床使用。

Observation of curative effect of nab-paclitaxel combined with cisplatin or carboplatin in the treatment of advanced NSCLC

Objective To evaluate the efficacy and toxicity of nab-paclitaxe combined with cisplatin or carboplatin as first-line or second-line chemotherapy in the treatment of patients with advanced NSCLC.Methods 82 patients were randomly divided into two groups,which were respectively given the first-line and second-line chemotherapy.Their OR,RR,TTP,OS and 1-year survival rate were compared.Results The overall response rate was 21.95 ％ （18/82）,the control rate was 73.17％,TTP was 6.3 months,and the median survival time was 10.3 months.The adverse reactions were tolerable.Conclusion Nab-paclitaxe combined with cisplatin or carboplatin as first-line or second-line chemotherapy is effective and the adverse effect is well tolerable in the treatment of patients with advanced NSCLC.